Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018, Article ID 1942648, 7 pages
https://doi.org/10.1155/2018/1942648
Research Article

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease

1Department of Upper GI, Unit of Liver Diseases, Karolinska University Hospital, Stockholm, Sweden
2Department of Medicine, Huddinge Karolinska Institutet, Stockholm, Sweden

Correspondence should be addressed to Per Stål; es.ik@lats.rep

Received 25 April 2018; Accepted 12 June 2018; Published 2 July 2018

Academic Editor: Mario Pirisi

Copyright © 2018 Hannes Hagström et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Loomba and A. J. Sanyal, “The global NAFLD epidemic,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 686–690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Q. M. Anstee, G. Targher, and C. P. Day, “Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 6, pp. 330–344, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Holmer, E. Melum, H. Isoniemi et al., “Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries,” Liver International, 2018. View at Publisher · View at Google Scholar
  4. N. M. W. de Alwis and C. P. Day, “Non-alcoholic fatty liver disease: the mist gradually clears,” Journal of Hepatology, vol. 48, Supplement 1, pp. S104–S112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Hagström, P. Nasr, M. Ekstedt et al., “Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD,” Journal of Hepatology, vol. 67, no. 6, pp. 1265–1273, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ekstedt, H. Hagström, P. Nasr et al., “Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up,” Hepatology, vol. 61, no. 5, pp. 1547–1554, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Angulo, D. E. Kleiner, S. Dam-Larsen et al., “Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease,” Gastroenterology, vol. 149, no. 2, pp. 389–397.e10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. McPherson, T. Hardy, E. Henderson, A. D. Burt, C. P. Day, and Q. M. Anstee, “Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management,” Journal of Hepatology, vol. 62, no. 5, pp. 1148–1155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Pelusi, S. Petta, C. Rosso et al., “Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease,” PLoS One, vol. 11, no. 9, article e0163069, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Bjorkstrom, P. Stal, R. Hultcrantz, and H. Hagstrom, “Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with non-alcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 15, no. 9, pp. 1461–1468, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. D. E. Kleiner, E. M. Brunt, M. van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Bedossa, “Current histological classification of NAFLD: strength and limitations,” Hepatology International, vol. 7, Suppl 2, pp. 765–770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad, and R. Loomba, “Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies,” Clinical Gastroenterology and Hepatology, vol. 13, no. 4, pp. 643–654.e9, 2015, e649. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Adams, S. Sanderson, K. D. Lindor, and P. Angulo, “The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies,” Journal of Hepatology, vol. 42, no. 1, pp. 132–138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. V. W. S. Wong, G. L. H. Wong, P. C. L. Choi et al., “Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years,” Gut, vol. 59, no. 7, pp. 969–974, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S. P. O. Jansson, K. Fall, O. Brus et al., “Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden,” Diabetic Medicine, vol. 32, no. 10, pp. 1319–1328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. de Munter, P. Tynelius, C. Magnusson, and F. Rasmussen, “Longitudinal analysis of lifestyle habits in relation to body mass index, onset of overweight and obesity: results from a large population-based cohort in Sweden,” Scandinavian Journal of Public Health, vol. 43, no. 3, pp. 236–245, 2015. View at Publisher · View at Google Scholar · View at Scopus